Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
Summary
VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the Company or Rakovina Therapeutics) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies is pleased to announce the undertaking of a non-brokered Private Placement (the Offering) for gross proceeds of up to $1.5 million at a purchase price of $0.10 per Unit. Rakovina Therapeutics intends to advance these validated drug candidates to clinical trials in collaboration with pharmaceutical partners.The Units will be sold on a non-brokered private placement basis in accordance with applicable Canadian securities laws and under applicable exemptions from prospectus and registration requirements and the securities will be subject to resale restrictions for a period of four months plus one day from the date of issue.About Rakovina Therapeutics Inc.Rakovina Therapeutics Inc. is focused on the development of new cancer treatments based on novel DNA-damage response technologies. The Company has established a pipeline of novel DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials and obtaining marketing approval for new cancer therapeutics from Health Canada, the United States Food and Drug Administration and similar international regulatory agencies. Often, but not always, forward-looking statements can be identified by the use of words such as plans, is expected, expects, scheduled, intends, contemplates, anticipates, believes, proposes or variations (including negative variations) of such words and phrases, or state that certain actions, events, or results may, could, would, might or will be taken, occur or be achieved. The reader is referred to the Companys most recent filings on SEDAR for a more complete discussion of all applicable risk factors and their potential effects, copies of which may be accessed through the Companys profile page at www.sedar.com.For Further Information Contact:David Hyman, Chief Financial Officerinfo@rakovinatherapeutics.com